uric acid has been researched along with vildagliptin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Athyros, VG; Karagiannis, A; Katsiki, N | 1 |
| Abdel-Aal, M; Abdel-Ghany, RH; Alsemeh, AE; Ghareib, SA; Wahba, NS | 1 |
2 other study(ies) available for uric acid and vildagliptin
| Article | Year |
|---|---|
Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr
Topics: Adamantane; Egypt; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Uric Acid; Vildagliptin | 2017 |
Vitamin D3 potentiates the renoprotective effects of vildagliptin in a rat model of fructose/salt-induced insulin resistance.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cholecalciferol; Creatinine; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperuricemia; Hypoglycemic Agents; Insulin Resistance; Kidney; Kidney Cortex; Male; Malondialdehyde; MAP Kinase Signaling System; NADP; Oxidative Stress; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Sirtuin 1; Sodium Chloride; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Urea; Uric Acid; Vildagliptin | 2020 |